NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRXP NRX Pharmaceuticals Inc.

Pre-Mkt 02-23 07:53:15 EST

1.84

+0.00

0.00%

盘前1.84

+0.000.00%

06:29 EST

High1.85	Low1.77	Vol794.30K
Open1.82	D1 Closing1.84	Amplitude4.62%
Mkt Cap54.47M	Tradable Cap40.17M	Total Shares29.61M
T/O1.44M	T/O Rate3.64%	Tradable Shares21.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRXP","market":"US","secType":"STK","nameCN":"NRX Pharmaceuticals Inc.","latestPrice":1.84,"timestamp":1771621200000,"preClose":1.84,"halted":0,"volume":794297,"hourTrading":{"tag":"盘前","latestPrice":1.84,"preClose":1.84,"latestTime":"06:29 EST","volume":46,"amount":83.119999,"timestamp":1771846194409,"change":0,"changeRate":0,"amplitude":0.043478},"delay":0,"changeRate":0,"floatShares":21834000,"shares":29605200,"eps":-2.31,"marketStatus":"Pre-Mkt","change":0,"latestTime":"02-23 07:53:15 EST","open":1.82,"high":1.85,"low":1.765,"amount":1442628.3437713,"amplitude":0.046196,"askPrice":1.88,"askSize":10,"bidPrice":1.8,"bidSize":1197,"shortable":3,"etf":0,"ttmEps":-2.31,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771857000000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":1.84,"preHourTrading":{"tag":"盘前","latestPrice":1.84,"preClose":1.84,"latestTime":"06:29 EST","volume":46,"amount":83.119999,"timestamp":1771846194409,"change":0,"changeRate":0,"amplitude":0.043478},"postHourTrading":{"tag":"盘后","latestPrice":1.81,"preClose":1.84,"latestTime":"19:39 EST","volume":254,"amount":461.38,"timestamp":1771634361927,"change":-0.03,"changeRate":-0.016304,"amplitude":0.016304},"volumeRatio":1.8307409833963137,"impliedVol":1.8949,"impliedVolPercentile":0.664},"requestUrl":"/m/hq/s/NRXP","defaultTab":"news","newsList":[{"id":"2612744053","title":"NRX Pharmaceuticals Price Target Maintained With a $25.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2612744053","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612744053?lang=en_us&edition=fundamental","pubTime":"2026-02-19 01:06","pubTimestamp":1771434360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2026 12:06 ET (17:06 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2612499041","title":"NRX Pharmaceuticals Files Initial Beneficial Ownership Statement for Chief Operating Officer Joseph Michael Casper","url":"https://stock-news.laohu8.com/highlight/detail?id=2612499041","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612499041?lang=en_us&edition=fundamental","pubTime":"2026-02-18 08:00","pubTimestamp":1771372847,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. has filed an initial statement of beneficial ownership with the SEC. The filing names Joseph Michael Casper, Chief Operating Officer, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL10GBJm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NRX Pharmaceuticals Files Initial Beneficial Ownership Statement for Chief Operating Officer Joseph Michael Casper","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2612746886","title":"NRX Pharmaceuticals Inc - Files Prospectus for $20 Mln Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2612746886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612746886?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:21","pubTimestamp":1771338118,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD162:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2612452853","title":"NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2612452853","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612452853?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:54","pubTimestamp":1771332840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 17, 2026 07:54 ET (12:54 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2612545430","title":"BRIEF-Nrx Pharmaceuticals (NasdaqNrxp) Announces Path To New Drug Application With Real World Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2612545430","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612545430?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:28","pubTimestamp":1771331280,"startTime":"0","endTime":"0","summary":"BRIEF-Nrx Pharmaceuticals (NasdaqNrxp) Announces Path To New Drug Application With Real World Data Feb 17 (Reuters) - NRX Pharmaceuticals Inc NRXP.O:NRX PHARMACEUTICALS (NASDAQ:NRXP) ANNOUNCES PATH TO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA21MT7C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2612451678","title":"NRX Pharmaceuticals Advances NRX-100 Toward FDA Approval for Suicidal Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2612451678","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612451678?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:03","pubTimestamp":1771329784,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. announced completion of an in-person Type C guidance meeting with the US Food and Drug Administration regarding its preservative-free intravenous ketamine product, NRX-100, for the treatment of suicidal ideation in depression, including bipolar depression. Based on FDA guidance, NRx plans to use existing clinical trial data along with Real World Evidence from over 65,000 patients to support its New Drug Application. The company will work with the FDA to finalize the statistical analysis protocol for the Real World Evidence dataset. Study results have not yet been presented.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL9Y5TCN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","SG9999014013.SGD","BK4588","BK4585","BK4112","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014005.SGD","LU2210149790.SGD","NDAQ","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","NRXP","LU2095319765.USD","SG9999014021.USD","BK4007"],"gpt_icon":0},{"id":"2612745176","title":"NRX Pharmaceuticals: Will Use Clinical Trial Data in Hand With Proposed Real World Data From Osmind to Apply for NRX-100 Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2612745176","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612745176?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:00","pubTimestamp":1771329605,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA21MT7C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2612702451","title":"NRX Pharmaceuticals Inc - Believes Path for NRX-100 Approval Based on Existing Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2612702451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612702451?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:00","pubTimestamp":1771329605,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA21MT7C:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2612517014","title":"NRX Pharmaceuticals Inc - FDA Advises No Additional Nonclinical Data Needed for NRX Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2612517014","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612517014?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:00","pubTimestamp":1771329605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA21MT7C:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2612451865","title":"NRX Pharmaceuticals (Nasdaq:Nrxp) Announces Path to New Drug Application With Real World Data and Broader Proposed Indication for NRX-100 (Ketamine) Following Type C FDA Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2612451865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612451865?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:00","pubTimestamp":1771329605,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA21MT7C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2612276451","title":"NRX Pharmaceuticals Inc - Co to Seek Broader Indication for NRX-100 for Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2612276451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612276451?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:00","pubTimestamp":1771329605,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA21MT7C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2611193421","title":"NRx Pharmaceuticals Inc. Announces Date for 2025 Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2611193421","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611193421?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:34","pubTimestamp":1771018475,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. has announced that its upcoming annual meeting of stockholders will be conducted in a virtual-only format. During the meeting, shareholders will vote on several key proposals, including the election of Chaim Hurvitz and Michael Taylor as Class I members of the Board of Directors to serve until the 2028 annual meeting or until their successors are appointed and qualified. Additionally, shareholders will consider the approval of an amendment to the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan and the ratification of Weinberg & Company, P.A. as the company's independent auditors for the fiscal year ending December 31, 2025. Other business matters that may properly come before the meeting or any adjournments or postponements thereof may also be addressed.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL6bGFWC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2608813264","title":"NRX Pharmaceuticals ernennt Joseph M. Casper zum Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2608813264","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608813264?lang=en_us&edition=fundamental","pubTime":"2026-02-03 06:16","pubTimestamp":1770070616,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. hat die Ernennung von Joseph M. Casper zum Chief Operating Officer mit Wirkung zum 27. Januar 2026 bekannt gegeben. Casper bringt 35 Jahre Erfahrung in der Gesundheitsbranche mit und war zuvor in leitenden Positionen unter anderem bei Deloitte, First Consulting Group, Kaiser Permanente und Anthem ttig.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL5zgwts:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2603599802","title":"NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2603599802","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603599802?lang=en_us&edition=fundamental","pubTime":"2026-01-16 20:03","pubTimestamp":1768564980,"startTime":"0","endTime":"0","summary":"WILMINGTON, Del., Jan.  16, 2026  (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it will hold its annual ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/16/3220242/0/en/NRx-Pharmaceuticals-Nasdaq-NRXP-Announces-2025-Annual-Meeting-Date-and-Record-Date.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2603603772","title":"NRX Pharmaceuticals Price Target Maintained With a $25.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2603603772","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603603772?lang=en_us&edition=fundamental","pubTime":"2026-01-15 17:55","pubTimestamp":1768470900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 15, 2026 04:55 ET (09:55 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2603618007","title":"NRX Pharmaceuticals Submits Real-World Data to FDA for Accelerated Approval of NRX-100","url":"https://stock-news.laohu8.com/highlight/detail?id=2603618007","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603618007?lang=en_us&edition=fundamental","pubTime":"2026-01-14 20:03","pubTimestamp":1768392192,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals, Inc. has announced the submission of Real World Evidence  from over 70,000 patients in support of its application for Accelerated Approval of NRX-100  under Fast Track Designation for the treatment of suicidal ideation in depression and bipolar depression. The submission follows a recent policy change by the FDA allowing the inclusion of de-identified patient data in regulatory filings. Currently, there is no medicine approved specifically for the treatment of suicidal ideation, with Electroshock Therapy being the only FDA-approved intervention for this condition. The data, licensed from Osmind, will be presented to the FDA as part of the application process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL3cvGp9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2210149790.SGD","NRXP","BK4112","SG9999014005.SGD","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","BK4585","LU2095319765.USD","SG9999014021.USD","NDAQ"],"gpt_icon":0},{"id":"2603180976","title":"NRX Pharmaceuticals (Nasdaq:Nrxp) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to Be Submitted to the FDA in Support of NRX-100 Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2603180976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603180976?lang=en_us&edition=fundamental","pubTime":"2026-01-14 20:03","pubTimestamp":1768392180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nTUA9GLHTK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2601884929","title":"NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601884929","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601884929?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:41","pubTimestamp":1767620460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 05, 2026 08:41 ET (13:41 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2601688546","title":"NRX Pharmaceuticals and neurocare Group Launch Nationwide Network for Integrated Mental Health Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2601688546","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601688546?lang=en_us&edition=fundamental","pubTime":"2026-01-05 19:57","pubTimestamp":1767614234,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals Inc. has announced a partnership with neurocare Group AG to establish a nationwide network of clinics offering integrated neuroplastic care for Depression, PTSD, and other serious mental health disorders. The collaboration will merge neurocare’s expertise in neuromodulation technology with NRx’s neuroplastic drug development program, creating unified treatment protocols that combine Transcranial Magnetic Stimulation , ketamine and other neuroplastic drugs, hyperbaric oxygen therapy, and supportive psychotherapy. The initiative leverages neurocare’s network of over 400 Apollo TMS devices across the United States and aims to bring integrated treatment within driving distance of any American home by the end of 2026, with an initial focus on First Responders, Active Duty Military, and Veterans. The program also seeks to provide a single point of accountable care to payers and expand contracts with commercial and governmental health programs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLc2RhDB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014005.SGD","NRXP","BK4112","LU0314104364.USD","BK4588","NDAQ","SG9999014039.USD","BK4007","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2600057633","title":"NRX Pharmaceuticals Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2600057633","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600057633?lang=en_us&edition=fundamental","pubTime":"2026-01-02 17:59","pubTimestamp":1767347940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 02, 2026 04:59 ET (09:59 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.salbergco.com","stockEarnings":[{"period":"1week","weight":0.0222},{"period":"1month","weight":-0.1858},{"period":"3month","weight":-0.1362},{"period":"6month","weight":-0.303},{"period":"1year","weight":-0.249},{"period":"ytd","weight":-0.321}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.074525},{"month":2,"riseRate":0.2,"avgChangeRate":-0.104671},{"month":3,"riseRate":0.25,"avgChangeRate":-0.079214},{"month":4,"riseRate":0.25,"avgChangeRate":-0.225146},{"month":5,"riseRate":0.75,"avgChangeRate":0.071255},{"month":6,"riseRate":0.4,"avgChangeRate":-0.166652},{"month":7,"riseRate":0.4,"avgChangeRate":0.039708},{"month":8,"riseRate":0.2,"avgChangeRate":-0.14211},{"month":9,"riseRate":0.4,"avgChangeRate":-0.012776},{"month":10,"riseRate":0.6,"avgChangeRate":0.037482},{"month":11,"riseRate":0.4,"avgChangeRate":0.048439},{"month":12,"riseRate":0.6,"avgChangeRate":0.121824}],"exchange":"NASDAQ","name":"NRX Pharmaceuticals Inc.","nameEN":"NRX Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NRX Pharmaceuticals Inc.,NRXP,NRX Pharmaceuticals Inc.股票,NRX Pharmaceuticals Inc.股票老虎,NRX Pharmaceuticals Inc.股票老虎国际,NRX Pharmaceuticals Inc.行情,NRX Pharmaceuticals Inc.股票行情,NRX Pharmaceuticals Inc.股价,NRX Pharmaceuticals Inc.股市,NRX Pharmaceuticals Inc.股票价格,NRX Pharmaceuticals Inc.股票交易,NRX Pharmaceuticals Inc.股票购买,NRX Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}